Pelthos Therapeutics Reports $15.6M Revenue in Latest Quarter, Net Loss of $23.4M

Pelthos Therapeutics Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenues of $15.6 million for the quarter, a notable increase from zero revenues in the same period last year, primarily driven by net product revenues of $15.4 million from its recently launched product, Zelsuvmi. For the six months ended June 30, 2026, total revenues reached $26.5 million, again reflecting the successful commercialization of Zelsuvmi, which was launched in July 2025. However, the company also reported a net loss of $23.4 million for the quarter and $48.5 million for the six-month period, compared to losses of $3.4 million and $5.4 million, respectively, in the prior year.

The financial performance reflects substantial changes compared to the previous fiscal period, largely due to the impact of the merger with LNHC, which was completed on July 1, 2025. This merger not only brought Zelsuvmi into Pelthos's portfolio but also included the acquisition of additional FDA-approved products, Xepi and Xeglyze, which are expected to contribute to future revenues. The company has also expanded its workforce to support its commercialization efforts, with approximately 67 territory managers engaged in promoting Zelsuvmi.

Operationally, Pelthos has seen a significant increase in its cash position, with cash and cash equivalents rising to $24.2 million as of June 30, 2026, up from $18.0 million at the end of the previous fiscal year. The company’s total assets increased to $137.4 million, driven by the merger and the acquisition of new product rights. However, total liabilities also rose sharply to $138.9 million, primarily due to the issuance of convertible notes and the venture loan agreement, which has a principal amount of up to $50 million. The company has reported that three of its wholesaler customers accounted for 78% of its total gross accounts receivable, highlighting a concentration risk in its customer base.

Looking ahead, Pelthos is focused on the continued commercialization of Zelsuvmi and the planned launches of Xepi and Xeglyze, which are expected in 2027. The company has also secured a venture loan to support these efforts, with access to additional funds contingent on achieving specific revenue milestones. Despite the current net losses, management believes that the growth in product revenues and the strategic positioning of its product portfolio will enable the company to achieve profitability in the future. The company has expressed confidence in its ability to fund operations for at least the next twelve months, given its current cash position and projected revenue growth.